Flurbiprofen and intraocular pressure.
Systemic or topical administration of corticosteroids may produce a rise in intraocular pressure (IOP). Nonsteroidal anti-inflammatory drugs (NSAI drugs) are alternate therapy for ocular inflammatory disease. Flurbiprofen, a new NSAI drug, was tested in double-masked fashion to delineate its effect on IOP. Flurbiprofen did not alter IOP in known high corticosteroid responders nor did it block corticosteroid-induced ocular hypertension.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003907:Dexamethasone / Q000037:antagonists & inhibitors; D004311:Double-Blind Method; D005260:Female; D005480:Flurbiprofen / Q000494:pharmacology / Q000633:toxicity*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D011422:Propionates / Q000633:toxicity*
D011422:Propionates; D005480:Flurbiprofen; D003907:Dexamethasone